Novartis to Expand Its Portfolio with Regulus Acquisition

In a significant move that underscores Novartis AG's commitment to innovation in the biopharmaceutical sector, the company has announced its agreement to acquire Regulus Therapeutics Inc. This deal, valued at up to $1.7 billion, marks a pivotal moment for both companies and the patients they serve.

Deal Structure and Future Prospects

Under the terms of the agreement, Novartis will initiate the acquisition with a payment of $7.00 per share, totaling $0.8 billion. Regulus shareholders are set to benefit further from a contingent value right (CVR), which promises an additional $7.00 per share upon the regulatory approval of farabursen, Regulus' lead product candidate.

Leadership's Vision for the Future

"We are thrilled to join forces with Novartis, a leader in global development and commercialization, to advance farabursen for patients with ADPKD. This partnership represents a beacon of hope for those awaiting new treatment options," expressed Jay Hagan, CEO of Regulus Therapeutics.

Closing Timeline

The transaction is poised for completion in the latter half of 2025, pending the fulfillment of standard closing conditions and regulatory approvals.